These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 8805878

  • 1. Kinetics of viral clearance in plasma, peripheral blood mononuclear cells and lymph nodes.
    Lafeuillade A, Djediouane A, Poggi C, Profizi N, Costes O, Tamalet C.
    AIDS; 1996 Jun; 10(7):801-2. PubMed ID: 8805878
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
    Tamalet C, Lafeuillade A, Fantini J, Poggi C, Yahi N.
    AIDS; 1997 Jun; 11(7):895-901. PubMed ID: 9189215
    [Abstract] [Full Text] [Related]

  • 4. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
    Mayers D, Bethel J, Wainberg MA, Weislow O, Schnittman S.
    J Infect Dis; 1998 Jun; 177(6):1730-3. PubMed ID: 9607859
    [Abstract] [Full Text] [Related]

  • 5. Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.
    Girard PM, Schneider V, Dehée A, Mariot P, Jacomet C, Delphin N, Damond F, Carcelain G, Autran B, Saimot AG, Nicolas JC, Rozenbaum W.
    AIDS; 2001 Jan 26; 15(2):275-7. PubMed ID: 11216939
    [No Abstract] [Full Text] [Related]

  • 6. Focusing on the second phase of plasma HIV-1 RNA clearance.
    Lafeuillade A, Poggi C, Sayada C, Pellegrino P, Profizi N.
    AIDS; 1997 Feb 26; 11(2):264-6. PubMed ID: 9030385
    [No Abstract] [Full Text] [Related]

  • 7. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection.
    Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O.
    J Infect Dis; 1997 May 26; 175(5):1051-5. PubMed ID: 9129065
    [Abstract] [Full Text] [Related]

  • 8. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.
    Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, Brundage RC, Remmel RP.
    AIDS; 2000 Sep 29; 14(14):2137-44. PubMed ID: 11061655
    [Abstract] [Full Text] [Related]

  • 9. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B, Wintergerst U, Notheis G, Eberle J, Gürtler L, Belohradsky BH.
    J Pediatr; 1997 Feb 29; 130(2):293-9. PubMed ID: 9042135
    [Abstract] [Full Text] [Related]

  • 10. Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
    Lafeuillade A, Poggi C, Profizi N, Tamalet C, Costes O.
    J Infect Dis; 1996 Aug 29; 174(2):404-7. PubMed ID: 8699075
    [Abstract] [Full Text] [Related]

  • 11. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Aug 29; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 12. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
    Montaner JS, DeMasi R, Hill AM.
    AIDS; 1998 Mar 26; 12(5):F23-8. PubMed ID: 9543436
    [Abstract] [Full Text] [Related]

  • 13. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
    Molina JM, Chêne G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM.
    J Infect Dis; 1999 Aug 26; 180(2):351-8. PubMed ID: 10395849
    [Abstract] [Full Text] [Related]

  • 14. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.
    Wong JK, Günthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, Kwok S, Emini E, Richman DD.
    Proc Natl Acad Sci U S A; 1997 Nov 11; 94(23):12574-9. PubMed ID: 9356491
    [Abstract] [Full Text] [Related]

  • 15. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM, ACTG 303 Study Team.
    AIDS Res Hum Retroviruses; 2000 Sep 20; 16(14):1337-44. PubMed ID: 11018853
    [Abstract] [Full Text] [Related]

  • 16. Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy.
    Perrin L, Yerly S, Marchal F, Schockmel GA, Hirschel B, Fox CH, Pantaleo G.
    J Infect Dis; 1998 Jun 20; 177(6):1497-501. PubMed ID: 9607825
    [Abstract] [Full Text] [Related]

  • 17. Summaries for patients. Predictors of outcomes in patients with HIV infection treated with indinavir, zidovudine, and lamivudine.
    Ann Intern Med; 2001 Dec 04; 135(11):S-59. PubMed ID: 11759663
    [No Abstract] [Full Text] [Related]

  • 18. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ.
    Lancet; 1997 Oct 04; 350(9083):983-90. PubMed ID: 9329513
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM.
    JAMA; 1998 Mar 25; 279(12):930-7. PubMed ID: 9544767
    [Abstract] [Full Text] [Related]

  • 20. Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
    Katzenstein DA, Hughes MD, Albrecht M, Liou SH, Murphy R, Balfour H, Para M, Hammer S, ACTG 302 Study Team.
    AIDS Res Hum Retroviruses; 2001 Feb 10; 17(3):203-10. PubMed ID: 11177402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.